RICHMOND, Va., Oct 23, 2007 (BUSINESS WIRE) -- Insmed Inc. (Nasdaq:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York City.
The conference, to be held at the New York Palace Hotel, will run from Monday, November 5th through Wednesday, November 7th. Geoffrey Allan, Ph.D., Insmed's President and CEO, will make the presentation on Tuesday, November 6, 2007 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time).
"We look forward to participating at this important healthcare investor conference where we will provide an update on the progress of our dual-strategy growth plan based on our proprietary protein platform and the development and manufacture of follow-on biologics," said Dr. Allan.
The Company will also hold one-on-one meetings with investment firm representatives.
Individuals interested in listening to the live presentation via the Internet may do so by visiting www.insmed.com. A replay will be available on the Company's Web site for 30 days.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.
Forward Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the Company may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than the Company, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.